{"id":9779,"date":"2021-05-13T14:13:33","date_gmt":"2021-05-13T21:13:33","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9779"},"modified":"2021-05-14T14:14:11","modified_gmt":"2021-05-14T21:14:11","slug":"neutralization-potential-of-covishield-vaccinated-individuals-against-b-1-617-1","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/13\/neutralization-potential-of-covishield-vaccinated-individuals-against-b-1-617-1\/","title":{"rendered":"Neutralization Potential of Covishield Vaccinated Individuals against B.1.617.1"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Individuals with prior SARS-CoV-2 infection (n=18) had 24-fold higher levels of anti-SARS-CoV-2 neutralizing antibodies (nAbs) against the B.1.617.1 variant, which is linked to recent surges in cases in India, 4 weeks after the second dose of the Covishield vaccine (Oxford-AstraZeneca vaccine version manufactured in India), compared to those without a previous history of infection (n=43). Geometric mean titers (GMTs) for nAbs against the D614G variant among vaccinated individuals with prior infection were also 30-fold higher than vaccinated individuals without prior infection. Among vaccinated individuals without prior infection, neutralization titers against the B.1.617.1 variant were reduced 2-fold compared to those against the D614G variant .<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Yadav et al.\u00a0(May 12, 2021). Neutralization Potential of Covishield Vaccinated Individuals against B.1.617.1. Pre-print downloaded May 13 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.12.443645\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.12.443645<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Individuals with prior SARS-CoV-2 infection (n=18) had 24-fold higher levels of anti-SARS-CoV-2 neutralizing antibodies (nAbs) against the B.1.617.1 variant, which is linked to recent surges in cases in India, 4 weeks after the second dose of the Covishield vaccine (Oxford-AstraZeneca vaccine version manufactured in India), compared to those without a previous history&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/13\/neutralization-potential-of-covishield-vaccinated-individuals-against-b-1-617-1\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-9779","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9779"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9779\/revisions"}],"predecessor-version":[{"id":9780,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9779\/revisions\/9780"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9779"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}